Precision Spine Reaches Milestone with the Reform® Modular Pedicle Screw System

Precision Spine notes The Reform® Modular Pedicle Screw System, first introduced in April 2016, today reaches a monumental milepost, its 30,000th modular screw implantation.

This historic milestone is most impressive when highlighted by the fact that there have been no reported dissociations to date.

The Reform® Modular Pedicle Screw System provides surgeons with increased flexibility, versatility, and visibility to meet the varying requirements of degenerative and trauma procedures. The cobalt chrome and titanium tulips are available in both 5.5 and 4.75mm sizes, with standard and reduction options.

The system features Tru-Lock Technology that allows the tulip to be attached with a consistent attachment force, as well as a helpful audible click and tactile feel to confirm attachment.

The titanium modular cannulated and non-cannulated screws feature a minimally tapered, triple lead thread, as well as a self-starting aggressive screw tip and enlarged T25 drive feature ─ the combination of which delivers more immediate, secure bone engagement and maximum control during insertion.

The system’s modularity is intended to help increase the surgeon’s visibility in order to permit more thorough decortication of the surrounding fusion bed. A full complement of offset connectors, dominoes, hooks, and cross connectors increases procedure flexibility.

“The system’s modular design greatly enhances O.R. versatility and efficiency,” said Vikram Udani, M.D., “assisting surgeons with intraoperatively assembling a construct that achieves immediate bone purchase, with a pull-out strength that provides optimal security.”

“We are pleased and proud to document this event in our company annals,” said Chris DeNicola, the company’s Chief Operating Officer, “as it is further evidence of our continuing mission to provide patients and surgeons worldwide with safe and effective solutions for complex spinal pathologies. We view this milestone as validation of the great trust placed in the company by our distribution partners and the surgeons they serve and support.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version